Figure 1. The structures of compounds I, II and III.
Figure 2. Lead compound and structure-based design of the target compounds.
Scheme 1. Synthetic scheme for the synthesis of compounds 4a–i and 5a–i.
Table 1. Inhibitory activity (MIC*, µg/mL) of compounds 4a–i and 5a–i against bacteria.
Table 2. Inhibitory activity (MIC*, µg/mL) of compounds 4a–i and 5a–i against clinical isolates of multidrug-resistant Gram-positive strains.
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
To request a reprint or corporate permissions for this article, please click on the relevant link below:
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
Obtain permissions instantly via Rightslink by clicking on the button below:
If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.
